Simcere Pharmaceutical Group Ltd
02096
Company Profile
Business description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Contact
No. 699-18, Xuanwu Road
Xuanwu District
Jiangsu
Nanjing210042
CHNT: +86 2585566666
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
6,412
Stocks News & Analysis
stocks
2 undervalued ASX shares report
These two ASX shares are trading at a discount to our fair value.
stocks
Turmoil at WiseTech
Board members step down over differences on the role of former CEO Richard White.
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,503.20 | 56.90 | -0.66% |
| CAC 40 | 8,090.99 | 63.52 | -0.78% |
| DAX 40 | 22,425.93 | 138.37 | 0.62% |
| Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
| FTSE 100 | 8,658.98 | 0.39 | -0.00% |
| HKSE | 23,184.55 | 157.06 | -0.67% |
| NASDAQ | 19,286.93 | 237.08 | -1.21% |
| Nikkei 225 | 38,364.37 | 412.57 | -1.06% |
| NZX 50 Index | 12,363.34 | 168.38 | -1.34% |
| S&P 500 | 5,983.25 | 29.88 | -0.50% |
| S&P/ASX 200 | 8,255.70 | 52.50 | -0.63% |
| SSE Composite Index | 3,368.52 | 4.50 | -0.13% |